CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.
about
Underutilisation of routinely collected data in the HIV programme in Zambia: a review of quantitatively analysed peer-reviewed articles.The effect of tuberculosis on mortality in HIV positive people: a meta-analysis.Changing predictors of mortality over time from cART start: implications for care.Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan AfricaAn empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programsImproved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia.CD4 trajectory adjusting for dropout among HIV-positive patients receiving combination antiretroviral therapy in an East African HIV care centre.The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort.High rates of tuberculosis in patients accessing HAART in rural South Africa.Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital.Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
P2860
Q30491997-D2D407BB-F740-4382-A527-40C795AE49D1Q30994512-3BCDFD64-C621-4C66-9E3F-02AD8B57E303Q33564975-508AC2EE-F0FB-4161-9EE2-269B3E38BBE3Q33580153-9996393E-2714-4D08-896D-B516E503C6E0Q33774697-FF77165B-B269-485F-87D7-1C8B7C01A112Q33876965-67454F49-38D6-480C-9DE5-8B104A7A2E83Q34056071-EAE35BE7-E0D3-4456-B438-C3C65E052C6AQ34059861-690120FB-9A16-4928-82DB-EEE32A8847E3Q34451025-026153CC-8183-486A-96F9-63602BAFDFFBQ35549179-68482839-D288-4721-9B3B-AA1B62EDA942Q37617342-51533298-DA77-458D-A853-56D87F62BF64Q37619616-FD8B4877-5F3A-4959-9F1B-4F5549423F11Q37692805-DD3E7B8B-569E-474A-AD78-10A5B643037FQ39678239-23C2CC05-E882-458F-A8D3-7F328B83DEE2Q41649688-1382595D-87A7-46EB-90A2-4003B15744F7
P2860
CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@en
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@nl
type
label
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@en
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@nl
prefLabel
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@en
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@nl
P2093
P2860
P1476
CD4+ response and subsequent r ...... ral therapy in Lusaka, Zambia.
@en
P2093
Benjamin H Chi
Jeffrey S A Stringer
Mark Giganti
Mohammed Limbada
Priscilla L Mulenga
P2860
P304
P356
10.1097/QAI.0B013E3181AB6D8B
P407
P577
2009-09-01T00:00:00Z